2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult
PAPER

819 Transcriptional regulation by cyclin D1 in concert with IRF4 and NFkB suggests new therapeutic opportunities for t(11;14) multiple myeloma

Katrina Fordwor-Hepburn, MD, Jason Taslim, MSc2, Sophie S Ball3, Qizhen Jia4, Yiming Huang5, Aristeidis Chaidos, MD, PhD6, Pierangela Sabbattini, PhD7, Nick T Crump, PhD8, Anastasios Karadimitris9
1 Imperial College London, London, United Kingdom
2 Imperial College London, London, United Kingdom
3 Imperial College London, London, United Kingdom
4 Imperial College London, London, United Kingdom
5 Imperial College London, London, United Kingdom
6 Imperial College London, London, United Kingdom
7 Imperial College London, London, United Kingdom
8 Imperial College London, London, United Kingdom
9 Imperial College London, London, United Kingdom

Changes to the epigenome are increasingly recognised as important to myelomagenesis. Aberrant usage of oncogenic distal regulatory elements, such as enhancers, drives differential regulatory networks and transcriptional changes. The transcription factors (TFs) IRF4 and NF-kB are both over-active in myeloma and are associated with activation of super-enhancers and development of an oncogenic transcriptome.

In t(11;14), the most common myeloma translocation, oncogenic CCND1 is overexpressed by its juxtaposition to the IgH enhancer. In its canonical role, CCND1 (Cyclin D1) drives the G1-to-S cell cycle transition by activating CDK4/6-dependent phosphorylation of Rb, driving release of the transcription factor E2F1 and transcription of cell cycle genes. However, non-canonical cyclin D1 functions have been reported in other cancers, including transcriptional regulation.

 We sought to investigate whether, beyond cell cycle regulation, oncogenic cyclin D1 contributes to myelomagenesis by transcriptional deregulation.

Cyclin D1, E2F1, IRF4 and H3K27 ChIP-sequencing (ChIP-seq) was conducted in the t(11;14) myeloma cell lines U266 and KMS12. Results were integrated with patient RNA-seq from the MMRF CoMMpass dataset, comparing t(11;14) myelomas to other myeloma. We introduced an FKBP domain to the CCND1 locus using CRISPR-Cas9 to induce rapid, selective degradation of cyclin D1 upon addition of dTAGV-1. Western blot, cell cycle and growth assays were used to assess the impact of cyclin D1 loss. Cyclin D1 degradation was paired with POINT-seq at 6 hours and RNA-seq at 24 hours to observe nascent and later transcriptional changes. BETA analysis was used to link cyclin D1 chromatin binding with differentially expressed genes (DEGs). The on-chromatin interactors of cyclin D1 were captured by RIME.

Cyclin D1 ChIP-seq revealed 8046 chromatin binding sites. BETA integration with the CoMMpass dataset determined cyclin D1 to be an activator of t(11;14) patient-specific genes. 60% of cyclin D1 binding sites localized to gene promoters, of which 72% were also bound by E2F1. Consistent with the canonical role of cyclin D1, bound genes were enriched for DNA replication and DNA damage repair pathways. In addition, ChromHMM chromatin state analysis identified a novel cyclin D1 localization to enhancers, with corresponding target genes enriched for immune regulation. Motif analysis identified IRF4 and NF-kB binding motifs at enhancer cyclin D1 binding sites, while IRF4 ChIP-seq identified co-binding at 58% of cyclin D1 sites, including at key myeloma genes PRDM1, IRF4, XBP1 and BCL2. Similarly, there was a large overlap (49-63%) between cyclin D1 binding and published lymphoblastoid ChIP-seq for NF-kB subunits RELA, RELB, p50 and p52.

Using RIME, we identified 1556 significant on-chromatin cyclin D1 interactors, including its known partners CDK4, GSK3B and XPO1. In line with the ChIP-seq overlap, RIME also revealed interactions with IRF4 and multiple NF-kB subunits including RELB, RELA, p50 and p52, suggesting co-regulatory partnerships between cyclin D1 and these TFs.

Cyclin D1 degradation resulted in G1 phase arrest at 24 hours. ChIP-seq confirmed global loss of cyclin D1 from chromatin. Degradation for 6 hours resulted in 86 DEGs, which increased to 710 after 24 hours. Pathway enrichment identified canonical targets of cyclin D1 involved in cell cycle and DNA damage pathways and immune response. Approximately 40% of DEGs were associated with cyclin D1 binding. H3K27ac ChIP-seq showed widespread reduction in acetylation following cyclin D1 degradation. Consistent with this, BETA integration of the downregulated genes predicted cyclin D1 function as a transcriptional activator.

Gene set enrichment analysis of RNA-seq revealed a non-canonical function of cyclin D1 regulating of NF-kB signalling targets. The majority of cyclin D1-bound DEGs were also bound by IRF4. Furthermore,we found that downregulation of IRF4 by pomalidomide synergised with palbociclib, a CDK4/6 inhibitor, to suppress myeloma cell growth.

In conclusion, we found direct transcriptional regulation by cyclin D1, contributing to its known roles in the cell cycle and DNA damage repair. Importantly, we also identified a novel function for cyclin D1 at enhancers, where it functions in concert with the oncogenic TFs IRF4 and NF-kB. Our data suggests that palbociclib, in combination with drugs targeting IRF4 or NF-kB, may be an effective treatment for t(11;14) myeloma.

Katrina Fordwor-Hepburn, MD: No relevant conflicts of interest to declare.